Jim Simons Travere Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 2,495,114 shares of TVTX stock, worth $43.4 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

2,495,114

Previous 2,702,814 7.68%

Holding current value

$43.4 Million

Previous $48.4 Million 23.76%

% of portfolio

0.05%

Previous 0.08%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$13.49 - $21.54 $2.8 Million - $4.47 Million	-207,700 Reduced 7.68%	2,495,114 $36.9 Million
Q1 2025 May 14, 2025	BUY	$17.07 - $23.75 $5.01 Million - $6.97 Million	293,300 Added 12.17%	2,702,814 $48.4 Million
Q4 2024 Feb 13, 2025	BUY	$13.65 - $19.85 $7.3 Million - $10.6 Million	534,500 Added 28.51%	2,409,514 $42 Million
Q3 2024 Nov 13, 2024	SELL	$7.89 - $15.21 $2.59 Million - $5 Million	-328,800 Reduced 14.92%	1,875,014 $26.2 Million
Q2 2024 Aug 09, 2024	SELL	$5.26 - $8.28 $3.46 Million - $5.45 Million	-658,200 Reduced 23.0%	2,203,814 $18.1 Million
Q1 2024 May 13, 2024	SELL	$7.18 - $9.82 $1.57 Million - $2.15 Million	-219,000 Reduced 7.11%	2,862,014 $22.1 Million
Q4 2023 Feb 13, 2024	BUY	$5.44 - $9.5 $5.91 Million - $10.3 Million	1,086,892 Added 54.5%	3,081,014 $27.7 Million
Q3 2023 Nov 14, 2023	BUY	$7.64 - $17.25 $3.35 Million - $7.57 Million	439,109 Added 28.24%	1,994,122 $17.8 Million
Q2 2023 Aug 11, 2023	SELL	$15.3 - $22.61 $9.02 Million - $13.3 Million	-589,809 Reduced 27.5%	1,555,013 $23.9 Million
Q1 2023 May 12, 2023	BUY	$17.82 - $22.89 $9.82 Million - $12.6 Million	551,300 Added 34.6%	2,144,822 $48.2 Million
Q4 2022 Feb 13, 2023	BUY	$18.47 - $26.14 $1.59 Million - $2.25 Million	86,100 Added 5.71%	1,593,522 $33.5 Million
Q3 2022 Nov 14, 2022	SELL	$22.91 - $28.63 $3.43 Million - $4.28 Million	-149,600 Reduced 9.03%	1,507,422 $37.1 Million
Q2 2022 Aug 12, 2022	BUY	$20.94 - $30.01 $6.28 Million - $8.99 Million	299,700 Added 22.08%	1,657,022 $40.2 Million
Q1 2022 May 13, 2022	BUY	$23.61 - $30.6 $7.49 Million - $9.71 Million	317,400 Added 30.52%	1,357,322 $35 Million
Q4 2021 Feb 11, 2022	SELL	$24.34 - $31.17 $4.88 Million - $6.25 Million	-200,496 Reduced 16.16%	1,039,922 $32.3 Million
Q3 2021 Nov 12, 2021	SELL	$12.98 - $25.03 $6.11 Million - $11.8 Million	-470,904 Reduced 27.52%	1,240,418 $30.1 Million
Q2 2021 Aug 13, 2021	BUY	$14.11 - $26.4 $1.73 Million - $3.24 Million	122,600 Added 7.72%	1,711,322 $25 Million
Q1 2021 May 13, 2021	SELL	$23.37 - $31.77 $6.37 Million - $8.66 Million	-272,700 Reduced 14.65%	1,588,722 $39.7 Million
Q4 2020 Feb 10, 2021	BUY	$19.17 - $27.87 $35.7 Million - $51.9 Million	1,861,422 New	1,861,422 $50.7 Million

Others Institutions Holding TVTX

# of Institutions

230

Shares Held

102M

Call Options Held

1.71M

Put Options Held

401K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.12B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account